Closed Loop Medicine raises £2.1m pre-Series A

Closed Loop Medicine is helping doctors and healthcare providers to deliver personalised treatment regimens. The Cambridge-based health tech startup recently raised £2.1 million in venture capital funding.

The raise came from Longwall Venture Partners, IQ Capital and Martlet, the investment arm of the Marshall of Cambridge group. Also taking part in the financing were some leading Cambridge Angel investors, including Sherry Coutu CBE.

Closed Loop Medicine is a pioneering therapeutics companies, combining proven drug treatments with digital therapeutics.

Digital therapeutics are driven by high quality software programs, delivering evidence-based therapeutic interventions to patients, preventing, managing, or treating medical disorders or diseases.

The Closed Loop Medicine is providing a faster way of getting an individual to their optimum outcome by using data and insights about how a patient is responding to treatment to tailor drug and non-drug based therapy.

CEO and Co-Founder of Closed Loop Medicine; Dr Hakim Yadi OBE, said: “Having been in stealth mode for several years, this latest fund raising marks a significant milestone for the business and its founders.

“As well as securing venture capital funding from experienced investors in deep tech and life sciences, we have been able to establish corporate partnerships with international Pharma companies and the NHS, we have also hired a senior management team that represents the very best in talent across healthcare and technology.

“The funding will support the development of a drug + digital approach to treat and manage major health conditions our society faces, starting with sleep disturbance and hypertension. The company intends to develop fully regulated, evidence-based Drug + Digital solutions for the NHS and international healthcare providers.”

Thanks to this recent funding round, the company has taken offices in London, invested in technical product development, started clinical development and clinical trials and invested further in drug development.

In addition, the funding has been used to recruit the current management team and to support building out the CLM tech team.